AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2021

Apr 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2021-04-19

Reporting Person: Bowden Christopher (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-19	Common stock	M	3210	$35.16	Acquired	18697	Direct
2021-04-19	Common stock	S	3210	$55.1572	Disposed	15487	Direct
2021-04-20	Common stock	M	12513	$35.16	Acquired	28000	Direct
2021-04-20	Common stock	M	1888	$39.76	Acquired	29888	Direct
2021-04-20	Common stock	S	14401	$55.106	Disposed	15487	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-19	Stock option (right to buy)	$35.16	M	3210	Disposed	2024-05-30	Common stock (3210.0)	Direct
2021-04-20	Stock option (right to buy)	$35.16	M	12513	Disposed	2024-05-30	Common stock (12513.0)	Direct
2021-04-20	Stock option (right to buy)	$39.76	M	1888	Disposed	2026-02-15	Common stock (1888.0)	Direct

Footnotes

F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: Includes 77 shares purchased through the Company's employee stock purchase plan.

F3: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $55.00 to $55.40. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $55.00 to $55.34. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F6: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F7: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.